Sa. Brod, Autoimmunity is a type I interferon-deficiency syndrome corrected by ingested type IIFN via the GALT system, J INTERF CY, 19(8), 1999, pp. 841-852
Type I interferons (IFN-alpha/beta), products of the innate immune system,
can modulate immune function whereas proinflammatory IFN-gamma (type II IFN
), a product of the acquired immune system upregulates inflammation smd enh
ances cell mediated immunity. We have proposed a unifying hypothesis of the
origin of autoimmunity as a type I IFN immunodeficiency syndrome involving
inadequate regulation of the acquired immune system product IFN-gamma by t
he IFN-alpha/beta innate immune system. The common theme of ingested type I
IFNs in autoimmunity is inhibition of proinflammatory type II IFN systemic
ally or at the target organ. In multiple sclerosis (MS) and insulin-depende
nt diabetes mellitus (IDDM) at the target organ, and in rheumatoid arthriti
s (RA) as a regulator of other proinflammatory cytokines, IFN-gamma is the
nexus of inflammation in autoimmunity.. Ingested type I IFNs counteract typ
e II IFN, overcome the relative lack of type I IFN activity, and ameliorate
autoimmunity. The administration of type I IFNs (IFN-alpha/beta) via the g
ut offers an exciting alternative to systemic application for overcoming th
e type I IFN immunodeficiency in autoimmunity. Successful rise of ingested
type I IFN in three separate prototypical autoimmune diseases suggests a br
oad antiinflammatory therapeutic profile for this technology.